Glenmark Pharmaceuticals Inc., USA will launch its generic Sodium Phosphates Injection USP (15 mM P/5 mL, 45 mM P/15 mL, and 150 mM P/50 mL) in the U.S. in April 2026. As a bioequivalent, therapeutically equivalent alternative to Hospira, Inc.'s reference drug, these single-dose vials are designed for safe phosphorus supplementation.

According to IQVIA sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials market achieved annual sales of approximately $66.8 million.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We look forward to the upcoming launch of Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials, strengthening our commitment to bring to market quality and affordable alternatives for patients, while also further expanding our portfolio of products within the institutional channel.”